Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and External Validation of a Prognostic Staging System for Predicting Wound Complication after Internal Hemipelvectomy: An International Multicenter Study.

Journal of the American College of Surgeons·2026
Same author

Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

Science (New York, N.Y.)·2026
Same author

Pilot study evaluating tolerability and changes in fecal microbiota associated with novel probiotic administration to dogs with diarrhea.

Frontiers in veterinary science·2026
Same author

EGR1 Mediates Riluzole-Induced Apoptosis in Osteosarcoma via the Yap/p73-Bax Signaling Axis.

bioRxiv : the preprint server for biology·2025
Same author

A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Low prevalence of hemoperitoneum recurrence in dogs following splenectomy for benign splenic tumors.

Frontiers in veterinary science·2025
Same journal

Increased 18F-FDG Avidity on PET/CT During Treatment for Rhabdomyosarcoma Confirmed to Be Mature Rhabdomyoblasts.

Journal of pediatric hematology/oncology·2026
Same journal

Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors.

Journal of pediatric hematology/oncology·2026
Same journal

Frequent Use of Hematologic Testing in Children Admitted for Nonaccidental Trauma.

Journal of pediatric hematology/oncology·2026
Same journal

Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock.

Journal of pediatric hematology/oncology·2026
Same journal

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same journal

Diagnostic Pitfalls in Pediatric Acute Promyelocytic Leukemia: All-trans Retinoic Acid-Associated Hypercalcemia Mimicking Fungal Meningitis and the Risks of Azole Coadministration.

Journal of pediatric hematology/oncology·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Methods to Enable Spatial Transcriptomics of Bone Tissues
07:43

Methods to Enable Spatial Transcriptomics of Bone Tissues

Published on: May 3, 2024

Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray.

Tanasa S Osborne1, Ling Ren, John H Healey

  • 1Tumor and Metastasis Biology Section, Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA. osbornet@mail.nih.gov

Journal of Pediatric Hematology/Oncology
|September 24, 2011
PubMed
Summary
This summary is machine-generated.

Identifying biomarkers for osteosarcoma (OS) patient risk is crucial. This study found eukaryotic initiation factor 4E (eIF4E) expression did not correlate with OS patient outcomes.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Methods to Enable Spatial Transcriptomics of Bone Tissues
07:43

Methods to Enable Spatial Transcriptomics of Bone Tissues

Published on: May 3, 2024

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Predicting osteosarcoma (OS) metastatic progression and chemotherapy response remains challenging.
  • Novel biomarkers are needed for prognosis, metastasis prediction, and treatment response assessment in OS.
  • Tissue microarrays (TMAs) are valuable for validating protein biomarkers across patient cohorts.

Purpose of the Study:

  • To develop and utilize a novel outcome-linked TMA for osteosarcoma research.
  • To investigate the expression and prognostic significance of eukaryotic initiation factor 4E (eIF4E) in OS.
  • To assess the utility of the developed TMA for biomarker validation.

Main Methods:

  • Construction of a novel, outcome-linked osteosarcoma tissue microarray (TMA).
  • Immunohistochemical analysis of eukaryotic initiation factor 4E (eIF4E) expression in OS patient samples.
  • Correlation analysis between eIF4E expression and patient clinical outcomes.

Main Results:

  • Uniform expression of eIF4E was observed across all tested osteosarcoma patient samples.
  • No significant association was found between eIF4E expression levels and patient prognosis or metastatic status.
  • The novel OS TMA facilitated the assessment of eIF4E's role as a potential biomarker.

Conclusions:

  • The developed osteosarcoma TMA is a valuable tool for biomarker research.
  • Eukaryotic initiation factor 4E (eIF4E) expression is not a predictive biomarker for outcome in osteosarcoma.
  • Further research using the TMA is warranted to identify other relevant biomarkers for osteosarcoma.